indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2018
0102020002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose… (More)
Is this relevant?
2007
2007
BACKGROUND Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
UNLABELLED Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?